Alpha Glucosidase Inhibitor - Not Just A Diabetes Fighter?

Alpha Glucosidase is a type of enzyme found in intestines of all human beings and is responsible for breaking down carbohydrates to smaller sugar molecules like glucose, in order for the carbohydrates to be absorbed easily by the body. Alpha Glucosidase inhibitors work by competitive and reversible inhibition of these intestinal enzymes. These enzymes also break down carbohydrates but at a much slower rate to form the smaller glucose molecules. This slower rate of digestion ensures a delay in the formation and hence absorption of glucose in blood. Alpha Glucosidase inhibitor is found in drugs like Acarbose- Precose, Miglitol – Glyset and Voglibose. The basic function of all the drugs remains the same, which is slowing down carbohydrate catabolism. Minute differences are found between acarbose and migitol. Migitol resembles monosaccharide type of carbohydrate while the mechanism of action of acarbose is like that of an oligosaccharide. Another difference observed between the two varieties of drugs is with respect to its ability to be absorbed by the body. Migitol is absorbed comparatively well by the body than acarbose. Also, migitol is observed to have a dual action mechanism. It is capable of inhibiting another enzyme called pancreatic alpha-amylase along with alpha-glucosidase. According to Dr. Richard Miller, M.D., Ph.D., professor of pathology at the U-M Medical School and associate director of the U-M Geriatrics Center “The new results on acarbose support the idea that drugs may someday be developed to prevent many diseases while also slowing the aging process itself”. Dr. Richard Miller further says at, that because acarbose is known to be safe for long-term human use, it may be possible for clinical researchers to evaluate its effects on aging and age-related diseases, both in people who take the drug to treat their diabetes, and in healthy volunteers. Read the latest available research information on Alpha Glucosidase Inhibitor at .